MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia

(MedPage Today) -- SAN DIEGO -- Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, regardless of whether FLT3 internal...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news